Kanape Therapeutics

Kanape Therapeutics is a Swiss-based biotechnology company dedicated to the development of novel small molecule immunotherapies for cancer. The company's primary focus is on modulating the kynurenine pathway, a key metabolic route used by tumors to evade the immune system. By developing potent dual inhibitors of Indoleamine 2,3-dioxygenase 1 (IDO1) and Tryptophan 2,3-dioxygenase (TDO2), Kanape aims to restore anti-tumor immune responses. Their approach seeks to overcome the limitations of previous IDO-only inhibitors by addressing redundant pathways of immune suppression. The company is currently advancing its lead candidates through pre-clinical development for the treatment of various solid tumors. Kanape was incubated through the BaseLaunch accelerator in the Basel biotech hub.